SAN DIEGO, Aug. 21, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or "Company") (www.innovuspharma.com) (OTCQB:INNV), announced today the formation of a Clinical Advisory Board made up of top key opinion leaders in the fields of gynecology and sexual health to support the continued growth of its Zestra® product. The Clinical Advisory Board will work closely with the Innovus Pharma® management team in addressing health authorities, outlining clinical protocols and surveys, as well as presenting Innovus Pharma® at academic and industry meetings for its marketed and currently in-development products.
"We are very excited to bring the leading members in the fields of Sexual Health and Gynecology onto our Clinical Advisory Board. We believe that the quality of the members of the Clinical Advisory Board is a great testimony to the benefit of Zestra® to patients and to its clinical efficacy. These members will be instrumental in promoting the development, marketing and commercialization of our products to meet the growing demand in the global pharmaceutical market for products which foster sexual health and vitality," said Dr. Bassam Damaj, President and Chief Executive Officer.
The members of the Clinical Advisory Board include:
Dr. Michael L. Krychman (Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine located in Newport Beach California, USA);
Dr. Gilbert Bou Jaoudé (Manager of the Center of Treatment and Research for the Reproductive Tract and Psychosomatic Diseases (ETPARP Center), located in Lille, France and President of the French-speaking Society for Sexual Medicine (SFMS), an affiliate of the European Society for Sexual Medicine (ESSM));
Dr. Susan Kellogg-Spadt (Director of Female Sexual Medicine at Academic Urology Center for Pelvic Medicine in Bryn Mawr, Pennsylvania, USA);
Dr. Rosella Nappi (Associate Professor of Obstetrics and Gynecology at the Research Center for Reproductive Medicine and Director of the Gynecological Endocrinology & Menopause Unit at the IRCCS San Matteo Foundation, University of Pavia, Italy); and
Dr. Santiago Palacios (Director of the Palacios' Institute of Women's Health, in Madrid, Spain, and President of the Spanish Foundation for Women and Health (FEMYS), Spain).
Each Clinical Advisory Board Member's full biography will be available at www.innovuspharma.com.
Zestra® is the only OTC natural product clinically proven in two U.S. double-blind, placebo controlled trials in 276 women to increase arousal, desire and satisfaction during sexual intercourse. Zestra® is recommended by top therapists and gynecologists and is currently commercialized in the U.S. and Canada and has sold millions of units since its launch in 2007.
Zestra® is currently sold in close to 1,700 retail stores in the United States with Walmart being the largest retail chain with 1,400 of its superstores. In addition, Zestra® is available through wholesale drug distributors such as Cardinal Health and McKesson.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma® is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of four marketed products in this space including CIRCUMSerum® (to be re-named SenSum+™) (for sales outside the U.S. only) and Zestra Glide®.
For more information, go to www.innovuspharma.com.
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra®, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.